Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JENNEFER C SUTTON

Allopathic & Osteopathic Physicians Family Medicine

NPI
1790776276
CMS profile
35506
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$137.60

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $137.60 2

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Novo Nordisk Inc $118.52 1
Organon LLC $19.08 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JENNEFER C SUTTON

NPI 1790776276 · CMS profile ID 35506

Allopathic & Osteopathic Physicians / Family Medicine

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1790776276?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JENNEFER C SUTTON, NPI 1790776276, CMS profile ID 35506. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790776276?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JENNEFER C SUTTON, NPI 1790776276, CMS profile ID 35506. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790776276?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JENNEFER C SUTTON, NPI 1790776276, CMS profile ID 35506, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1790776276?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $137.60 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $118.5202/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002105183 CMS
Organon LLC $19.0802/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1046796385 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $25.00 1
PY2023 $137.60 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $10,213.20 3
PY2024 Principal investigator $25,917.10 4
PY2023 Principal investigator $79,360.24 21
PY2022 Principal investigator $137,134.84 242
PY2021 Principal investigator $139,829.55 300
PY2020 Principal investigator $92,369.23 83
PY2019 Principal investigator $165,436.14 99

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

300 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novo Nordisk AS $70.00 12/31/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 833636157
Principal investigator 1 Novo Nordisk AS $13,124.43 12/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811451397
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 12/17/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838455343
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 12/17/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838455350
Principal investigator 1 Novo Nordisk AS $50.12 12/13/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811831033
Principal investigator 1 Novo Nordisk AS $23.06 12/07/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811831031
Principal investigator 1 Novo Nordisk AS $70.00 11/30/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 833636159
Principal investigator 1 Novo Nordisk AS $11,759.98 11/24/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811113159
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838449529
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838449537
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838449547
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838449555
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838449563
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838449571
Principal investigator 1 Novo Nordisk AS $2.24 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811782113
Principal investigator 1 Novo Nordisk AS $2.24 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811782115
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811782117
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811782119
Principal investigator 1 Novo Nordisk AS $5.69 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811782121
Principal investigator 1 Novo Nordisk AS $4.99 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811782123
Principal investigator 1 Novo Nordisk AS $4.99 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811782125
Principal investigator 1 Novo Nordisk AS $2.24 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811782127
Principal investigator 1 Novo Nordisk AS $2.24 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811782129
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811782131
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811782133
Principal investigator 1 Novo Nordisk AS $5.69 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811782135
Principal investigator 1 Novo Nordisk AS $5.69 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811782137
Principal investigator 1 Novo Nordisk AS $5.69 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811782139
Principal investigator 1 Novo Nordisk AS $5.69 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811782141
Principal investigator 1 Novo Nordisk AS $4.99 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811782249
Principal investigator 1 Novo Nordisk AS $4.99 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811782251
Principal investigator 1 Novo Nordisk AS $4.99 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811782253
Principal investigator 1 Novo Nordisk AS $4.99 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811782255
Principal investigator 1 Novo Nordisk AS $2.24 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811782257
Principal investigator 1 Novo Nordisk AS $2.24 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811782259
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811782261
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811782263
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811782265
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811782267
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811782269
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811782271
Principal investigator 1 Novo Nordisk AS $1.48 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811782273
Principal investigator 1 Novo Nordisk AS $5.69 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811782275
Principal investigator 1 Novo Nordisk AS $5.69 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811782277
Principal investigator 1 Novo Nordisk AS $5.69 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811782279
Principal investigator 1 Novo Nordisk AS $4.99 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811782281
Principal investigator 1 Novo Nordisk AS $4.99 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811782283
Principal investigator 1 Novo Nordisk AS $4.99 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811782285
Principal investigator 1 Novo Nordisk AS $4.99 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811782287
Principal investigator 1 Novo Nordisk AS $2.24 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811784349
Principal investigator 1 Novo Nordisk AS $5.69 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811809865
Principal investigator 1 Novo Nordisk AS $5.69 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811809867
Principal investigator 1 Novo Nordisk AS $5.69 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811809869
Principal investigator 1 Novo Nordisk AS $2.24 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811809871
Principal investigator 1 Novo Nordisk AS $2.24 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811809873
Principal investigator 1 Novo Nordisk AS $2.24 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811809875
Principal investigator 1 Novo Nordisk AS $2.24 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811809877
Principal investigator 1 Novo Nordisk AS $2.24 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811809879
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811809881
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811809883
Principal investigator 1 Novo Nordisk AS $5.69 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811809921
Principal investigator 1 Novo Nordisk AS $4.99 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811809923
Principal investigator 1 Novo Nordisk AS $2.24 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811809925
Principal investigator 1 Novo Nordisk AS $2.24 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811809927
Principal investigator 1 Novo Nordisk AS $2.24 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811809929
Principal investigator 1 Novo Nordisk AS $2.24 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811809931
Principal investigator 1 Novo Nordisk AS $2.24 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811809933
Principal investigator 1 Novo Nordisk AS $2.24 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811809935
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811809937
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811809939
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811809941
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811809943
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811809945
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811809947
Principal investigator 1 Novo Nordisk AS $5.69 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811809949
Principal investigator 1 Novo Nordisk AS $5.69 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811809951
Principal investigator 1 Novo Nordisk AS $5.69 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811809953
Principal investigator 1 Novo Nordisk AS $5.69 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811809955
Principal investigator 1 Novo Nordisk AS $5.69 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811809957
Principal investigator 1 Novo Nordisk AS $5.69 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811809959
Principal investigator 1 Novo Nordisk AS $4.99 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811809961
Principal investigator 1 Novo Nordisk AS $4.99 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811809963
Principal investigator 1 Novo Nordisk AS $4.99 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811809965
Principal investigator 1 Novo Nordisk AS $5.10 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811809967
Principal investigator 1 Novo Nordisk AS $60.00 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811809969
Principal investigator 1 Novo Nordisk AS $6.50 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811809971
Principal investigator 1 Novo Nordisk AS $9.00 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811809973
Principal investigator 1 Novo Nordisk AS $36.00 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811809975
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811898941
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811898943
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811898945
Principal investigator 1 Novo Nordisk AS $5.69 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811898947
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811898949
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811898951
Principal investigator 1 Novo Nordisk AS $5.69 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811898953
Principal investigator 1 Novo Nordisk AS $5.69 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811898955
Principal investigator 1 Novo Nordisk AS $4.99 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811898957
Principal investigator 1 Novo Nordisk AS $4.99 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811898959
Principal investigator 1 Novo Nordisk AS $2.24 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811898961
Principal investigator 1 Novo Nordisk AS $2.24 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811898963
Principal investigator 1 Novo Nordisk AS $2.24 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811898965
Principal investigator 1 Novo Nordisk AS $2.24 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811898967
Principal investigator 1 Novo Nordisk AS $2.24 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811898969
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811898971
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811898973
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811898975
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811898977
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811898979
Principal investigator 1 Novo Nordisk AS $5.69 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811898981
Principal investigator 1 Novo Nordisk AS $5.69 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811898983
Principal investigator 1 Novo Nordisk AS $5.69 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811898985
Principal investigator 1 Novo Nordisk AS $5.69 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811898987
Principal investigator 1 Novo Nordisk AS $5.69 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811898989
Principal investigator 1 Novo Nordisk AS $5.69 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811898991
Principal investigator 1 Novo Nordisk AS $5.69 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811898993
Principal investigator 1 Novo Nordisk AS $5.69 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811898995
Principal investigator 1 Novo Nordisk AS $4.99 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811898997
Principal investigator 1 Novo Nordisk AS $4.99 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811898999
Principal investigator 1 Novo Nordisk AS $4.99 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811899001
Principal investigator 1 Novo Nordisk AS $50.00 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811899003
Principal investigator 1 Novo Nordisk AS $9.00 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811899005
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811910433
Principal investigator 1 Novo Nordisk AS $5.69 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811910435
Principal investigator 1 Novo Nordisk AS $4.99 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811910437
Principal investigator 1 Novo Nordisk AS $4.99 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811910439
Principal investigator 1 Novo Nordisk AS $4.99 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811910441
Principal investigator 1 Novo Nordisk AS $4.99 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811910443
Principal investigator 1 Novo Nordisk AS $2.24 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811910445
Principal investigator 1 Novo Nordisk AS $2.24 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811910447
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811910449
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811910451
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811910453
Principal investigator 1 Novo Nordisk AS $5.69 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811910455
Principal investigator 1 Novo Nordisk AS $5.69 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811910457
Principal investigator 1 Novo Nordisk AS $4.99 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811910459
Principal investigator 1 Novo Nordisk AS $2.24 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811910461
Principal investigator 1 Novo Nordisk AS $2.24 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811910463
Principal investigator 1 Novo Nordisk AS $2.24 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811910465
Principal investigator 1 Novo Nordisk AS $2.24 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811910467
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811910469
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811910471
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811910473
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811910475
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811910477
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811910479
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811910481
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811910483
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811910485
Principal investigator 1 Novo Nordisk AS $3.05 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811910487
Principal investigator 1 Novo Nordisk AS $5.69 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811910489
Principal investigator 1 Novo Nordisk AS $5.69 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811910491
Principal investigator 1 Novo Nordisk AS $5.69 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811910493
Principal investigator 1 Novo Nordisk AS $5.69 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811910495
Principal investigator 1 Novo Nordisk AS $5.69 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811910497
Principal investigator 1 Novo Nordisk AS $5.69 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811910499
Principal investigator 1 Novo Nordisk AS $5.69 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811910501
Principal investigator 1 Novo Nordisk AS $4.99 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811910503
Principal investigator 1 Novo Nordisk AS $4.99 11/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9389-4606 No dispute reported 06/30/2026 811910505
Principal investigator 1 Novo Nordisk AS $23.06 11/18/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811113135
Principal investigator 1 ABBVIE INC. $700.25 11/17/2021 Non-covered Recipient Entity
VIP TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792482945
Principal investigator 1 Novo Nordisk AS $25.06 11/16/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811831029
Principal investigator 1 ABBVIE INC. $610.20 11/10/2021 Non-covered Recipient Entity
VIP TRIALS
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792482383
Principal investigator 1 Novo Nordisk AS $25.06 11/03/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811831027
Principal investigator 1 Novo Nordisk AS $70.00 10/29/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 833636161
Principal investigator 1 Novo Nordisk AS $25.06 10/28/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811113121
Principal investigator 1 Novo Nordisk AS $25.06 10/27/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811113109
Principal investigator 1 Novo Nordisk AS $10,638.54 10/27/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811113149
Principal investigator 1 Novo Nordisk AS $25.06 10/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811113095
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 10/22/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838441449
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 10/22/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838441457
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 10/22/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838441465
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 10/22/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838441473
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 10/22/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838441481
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 10/22/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838441487
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 10/22/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838441495
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 10/22/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838441503
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 10/22/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838441509
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 10/22/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838441517
Principal investigator 1 Novo Nordisk AS $25.06 10/13/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811112847
Principal investigator 1 ABBVIE INC. $947.05 10/07/2021 Non-covered Recipient Entity
VIP TRIALS
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792478483
Principal investigator 1 Novo Nordisk AS $70.00 09/30/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811831021
Principal investigator 1 Novo Nordisk AS $11,707.74 09/27/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811451350
Principal investigator 1 Novo Nordisk AS $50.12 09/20/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811805905
Principal investigator 1 Novo Nordisk AS $13.50 09/10/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811112807
Principal investigator 1 Novo Nordisk AS $9.75 09/10/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811451331
Principal investigator 1 Novo Nordisk AS $13.50 09/10/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811451415
Principal investigator 1 Novo Nordisk AS $54.00 09/10/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811805903
Principal investigator 1 Novo Nordisk AS $90.00 09/10/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811831013
Principal investigator 1 Novo Nordisk AS $7.65 09/10/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811831039
Principal investigator 1 Novo Nordisk AS $23.06 09/07/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811113201
Principal investigator 1 Novo Nordisk AS $70.00 08/31/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811805909
Principal investigator 1 ABBVIE INC. $330.75 08/30/2021 Non-covered Recipient Entity
VIP TRIALS
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792473103
Principal investigator 1 Novo Nordisk AS $46.12 08/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811451341
Principal investigator 1 Novo Nordisk AS $16,074.45 08/25/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811831023
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 08/24/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838433845
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 08/24/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838433855
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 08/24/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838433861
Principal investigator 1 Novo Nordisk AS $7.65 08/10/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811113171
Principal investigator 1 Novo Nordisk AS $9.75 08/10/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811113185
Principal investigator 1 Novo Nordisk AS $90.00 08/10/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811451407
Principal investigator 1 Novo Nordisk AS $13.50 08/10/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811805913
Principal investigator 1 Novo Nordisk AS $13.50 08/10/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811805915
Principal investigator 1 Novo Nordisk AS $54.00 08/10/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811831037
Principal investigator 1 ABBVIE INC. $450.00 08/05/2021 Non-covered Recipient Entity
VIP TRIALS
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792471621
Principal investigator 1 Novo Nordisk AS $23.06 08/05/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811451379
Principal investigator 1 Novo Nordisk AS $23.06 08/04/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811451389
Principal investigator 1 Novo Nordisk AS $23.06 08/03/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811831035
Principal investigator 1 Novo Nordisk AS $70.00 07/30/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811112821
Principal investigator 1 ABBVIE INC. $1,042.20 07/29/2021 Non-covered Recipient Entity
VIP TRIALS
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792469937
Principal investigator 1 Esperion Therapeutics, Inc. $739.80 07/27/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838428977
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 07/27/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838428983
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 07/27/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838428991
Principal investigator 1 Esperion Therapeutics, Inc. $389.00 07/27/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838428999
Principal investigator 1 Novo Nordisk AS $2,500.00 07/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811112833
Principal investigator 1 ABBVIE INC. $2,402.10 07/21/2021 Non-covered Recipient Entity
VIP TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792468205
Principal investigator 1 ABBVIE INC. $1,555.90 06/30/2021 Non-covered Recipient Entity
VIP TRIALS
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792464959
Principal investigator 1 Novo Nordisk AS $70.00 06/30/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811805907
Principal investigator 1 Novo Nordisk AS $1,250.00 06/28/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811113213
Principal investigator 1 Novo Nordisk AS $500.00 06/28/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811831003
Principal investigator 1 Novo Nordisk AS $5,000.00 06/28/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811831041
Principal investigator 1 Novo Nordisk AS $7.95 06/25/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811451359
Principal investigator 1 Novo Nordisk AS $90.00 06/25/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811451369
Principal investigator 1 Novo Nordisk AS $9.75 06/25/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811805901
Principal investigator 1 Novo Nordisk AS $13.50 06/25/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811805911
Principal investigator 1 Novo Nordisk AS $13.50 06/25/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811831009
Principal investigator 1 Novo Nordisk AS $54.00 06/25/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811831011
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 06/22/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838419455
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 06/22/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838419463
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 06/22/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838419469
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 06/22/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838419477
Principal investigator 1 Esperion Therapeutics, Inc. $389.00 06/22/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838419485
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 06/22/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838419493
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 06/22/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838419501
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 06/01/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838416179
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 06/01/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838416187
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 06/01/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838416195
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 06/01/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838416203
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 06/01/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838416209
Principal investigator 1 ABBVIE INC. $103.95 05/31/2021 Non-covered Recipient Entity
VIP TRIALS
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792461355
Principal investigator 1 ABBVIE INC. $103.95 05/31/2021 Non-covered Recipient Entity
VIP TRIALS
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792461357
Principal investigator 1 Novo Nordisk AS $70.00 05/31/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811831019
Principal investigator 1 ABBVIE INC. $1,614.00 05/28/2021 Non-covered Recipient Entity
VIP TRIALS
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792461303
Principal investigator 1 ABBVIE INC. $103.95 05/28/2021 Non-covered Recipient Entity
VIP TRIALS
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792461305
Principal investigator 1 ABBVIE INC. $103.95 05/28/2021 Non-covered Recipient Entity
VIP TRIALS
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792461307
Principal investigator 1 ABBVIE INC. $103.95 05/28/2021 Non-covered Recipient Entity
VIP TRIALS
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792461309
Principal investigator 1 ABBVIE INC. $207.90 05/28/2021 Non-covered Recipient Entity
VIP TRIALS
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792461311
Principal investigator 1 ABBVIE INC. $103.95 05/28/2021 Non-covered Recipient Entity
VIP TRIALS
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792461313
Principal investigator 1 ABBVIE INC. $103.95 05/28/2021 Non-covered Recipient Entity
VIP TRIALS
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792461315
Principal investigator 1 ABBVIE INC. $103.95 05/28/2021 Non-covered Recipient Entity
VIP TRIALS
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792461317
Principal investigator 1 ABBVIE INC. $461.70 05/28/2021 Non-covered Recipient Entity
VIP TRIALS
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792461319
Principal investigator 1 ABBVIE INC. $103.95 05/28/2021 Non-covered Recipient Entity
VIP TRIALS
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792461321
Principal investigator 1 ABBVIE INC. $103.95 05/28/2021 Non-covered Recipient Entity
VIP TRIALS
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792461323
Principal investigator 1 ABBVIE INC. $103.95 05/28/2021 Non-covered Recipient Entity
VIP TRIALS
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792461325
Principal investigator 1 ABBVIE INC. $103.95 05/28/2021 Non-covered Recipient Entity
VIP TRIALS
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792461327
Principal investigator 1 ABBVIE INC. $815.40 05/28/2021 Non-covered Recipient Entity
VIP TRIALS
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792461329
Principal investigator 1 Novo Nordisk AS $6.26 05/21/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811112769
Principal investigator 1 Novo Nordisk AS $13.50 05/21/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811112783
Principal investigator 1 Novo Nordisk AS $90.00 05/21/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811112797
Principal investigator 1 Novo Nordisk AS $7.95 05/21/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811451311
Principal investigator 1 Novo Nordisk AS $54.00 05/21/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811451321
Principal investigator 1 Novo Nordisk AS $75.00 05/21/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811805893
Principal investigator 1 Novo Nordisk AS $19.17 05/21/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811805895
Principal investigator 1 Novo Nordisk AS $9.75 05/21/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811805897
Principal investigator 1 Novo Nordisk AS $13.50 05/21/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811805899
Principal investigator 1 Novo Nordisk AS $75.00 05/21/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811831005
Principal investigator 1 Novo Nordisk AS $20.25 05/21/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811831007
Principal investigator 1 Novo Nordisk AS $25.00 05/06/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811831015
Principal investigator 1 Novo Nordisk AS $75.00 05/06/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 811831017
Principal investigator 1 ABBVIE INC. $5,727.45 04/29/2021 Non-covered Recipient Entity
VIP TRIALS
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792449597
Principal investigator 1 ABBVIE INC. $103.95 04/27/2021 Non-covered Recipient Entity
VIP TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792447225
Principal investigator 1 Novo Nordisk AS $1,000.00 04/26/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4506 No dispute reported 06/30/2026 811811065
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 04/21/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838404393
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 04/21/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838404401
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 04/21/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838404409
Principal investigator 1 Esperion Therapeutics, Inc. $389.00 04/21/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838404415
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 04/21/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838404423
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 04/21/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838404431
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 04/21/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838404439
Principal investigator 1 ABBVIE INC. $571.05 04/09/2021 Non-covered Recipient Entity
VIP TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792444025
Principal investigator 1 Novo Nordisk AS $5,092.01 03/31/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4506 No dispute reported 06/30/2026 811760455
Principal investigator 1 ABBVIE INC. $610.20 03/30/2021 Non-covered Recipient Entity
VIP TRIALS
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792437629
Principal investigator 1 Novo Nordisk AS $500.00 03/24/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4506 No dispute reported 06/30/2026 811221275
Principal investigator 1 Novo Nordisk AS $1,000.00 03/24/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4506 No dispute reported 06/30/2026 811760449
Principal investigator 1 Novo Nordisk AS $1,000.00 03/24/2021 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4506 No dispute reported 06/30/2026 811811063
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 03/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838402207
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 03/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838402215
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 03/23/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838402223
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 03/01/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838397191
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 03/01/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838397199
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 03/01/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838397207
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 03/01/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838397215
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 03/01/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838397223
Principal investigator 1 ABBVIE INC. $3,920.00 02/12/2021 Non-covered Recipient Entity
VIP TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792423135
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 02/01/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838390713
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 02/01/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838390723
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 02/01/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838390733
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 02/01/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838390741
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 02/01/2021 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838390749
Principal investigator 1 ABBVIE INC. $700.25 01/29/2021 Non-covered Recipient Entity
VIP TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792418727
Principal investigator 1 ABBVIE INC. $7,269.10 01/28/2021 Non-covered Recipient Entity
VIP TRIALS
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792415159